Presentation purpose; use. This document has solely the purposes of (i) providing summary information regarding Lyfebulb. (together with its investment management and other affiliates) (the “Firm”); (ii) determining your level of

interest in investing or co-investing with Lyfebulb. (the “Fund”); and (iii) providing general background information on the anticipated operations of the Firm and the Fund. This document may not be used for any other purpose

without the Firm’s prior written consent. Fund Characteristics; No Diversification. This presentation outlines, for illustrative purposes only, certain expected Fund characteristics. The Fund is in a structuring phase and the structure,

term, and general parameters described herein may be materially changed before any interests in the Fund are offered. The Fund’s actual structure, including its portfolio composition, will be determined over the course of the

investment period. Consequently, the Fund’s actual portfolio composition may differ materially from the parameters presented in this presentation, and may change over time.

KARIN HEHENBERGER, MD, PHD

CEO AND FOUNDER

VENTURES

2LYFEBULB OVERVIEW

• Chronic disease affects 50% of the population, is a rapidly growing global market with huge unmet patient needs – but the customer, ie the patient is disconnected from the providers and manufacturers

• Founded by Dr Karin Hehenberger, Dr Steve Squinto, Venture partner Orbimed and Riccardo Braglia, CEO Helsinn

• Lyfebulb connects industry with patients, enabling access to data, innovation and consumers

• Patient entrepreneur challenges in chronic disease areas: drive innovation, bridge gaps and engage the customer

• Patient ambassadors are passionate leaders in the community who create marketing opportunities for companies

• Captive and empowered network through online and live activities: social media, live events, books, ecommerce site and speaking engagements

• Lyfebulb Ventures: an innovation fund focused on diabetes and associated diseases

Lyfebulb functions as a bridge between industry and patient communities

LYFEBULB

LYFEBULB OVERVIEW

AGENDA

• Overview • Diabetes and Autoimmune

Disease • Team• Lyfebulb Ventures • Conclusions

LYFEBULB

4VISION

LYFEBULB

Lyfebulb Ventures is an early-stage Diabetes Innovation Venture Fund focused on breakthrough opportunities in diabetes with the goals to deliver a superior return on investment and to remove the burden of diabetes and other autoimmune diseases

5LYFEBULB VENTURES OVERVIEW

• Diabetes represents a large and rapidly growing global market with huge unmet medical needs

• There is an immense and untapped opportunity in type 1 diabetes (T1D), an autoimmune disease with a more aggressive and predictable disease progression, which can be extended to other autoimmune disease and insulin-dependent type 2 diabetes (T2D)

• Strong team, with a track record of building valuable companies, including diabetes experts, life sciences entrepreneurs and former executives, driven by a desire to remove the burden of diabetes while returning a profit to investors

• Second to none global network in medical science, the corporate world and the investment community allowing for superior deal flow and favorable exit scenarios

LYFEBULB

LYFEBULB VENTURES OVERVIEW

DIABETES AND AUTOIMMUNITY ARE

PANDEMICS THAT KILL AND CRIPPLE

LYFEBULB

7

MOST COMMON CAUSE OF:• Kidney failure• Blindness• Amputations

5% OF ALL PEOPLE WITH DIABETES DIE FROM LOW BLOOD SUGAR EACH YEAR

4 TIMES HIGHER RISK OF:Stroke and heart attacks

INCREASED RISK OF:Alzheimer’s disease and depression

3rd MOST COMMON CAUSE OF DEATH IN THE US

DIABETES – GLOBAL PANDEMIC THAT KILLS AND CRIPPLES

415+ million

People worldwide have diabetes

$245 billion

$13,700

Total cost of diabetes in the US

Annual cost of living with

diabetes

29 million

People in the US have diabetes

86 million

People in the US with pre-diabetes

80%People with diabetes live

outside the US and Europe

5-10%

Type 1 diabetes of the total number

of people with diabetes

1.6 millionPeople are

diagnosed with diabetes each year

8

COMMON ETIOLOGY:• Similar genetic background • Both genes and environment play a role

WOMEN ARE MORE AFFECTED BY AUTOIMMUNE DISEASE THAN MEN

SYMPTOMS CROSS MULTIPLE ORGANS AND ACROSS MEDICAL SPECIALTIES

PEOPLE OFTEN HAVE MORE THAN ONE AUTOIMMUNE DISEASE

2/3 TOP-SELLING DRUGS 2016 WERE FOR AUTOIMMUNE DISEASES: HUMIRA AND REMICADE

AUTOIMMUNE DISEASES – MORE THAN 100 DIFFERENT KINDS

>100 billion

Lowball estimate for total cost

annually

1.3%

50 million

Hashimoto’s disease in the US

population

People in the US with autoimmune

disease

400,000

People in the US with MS

1.3 million

People in the US with Rheumatoid

Arthritis

1%

Celiac disease in the US population

2-3%

Psoriasis in the US population

1.6 million

People in the US with IBD

9DIABETES

LYFEBULB

• Insulin replacement, the only option in T1D and for many T2D, saves lives, but does not render people without risk of complications

• Both T1D and Insulin Dependent T2D are addressed by many of the same regenerative targets, growing the market by 4-5 times

• T1D is characterized by an inability to control blood sugar due to the loss of insulin secreting cells (beta-cells) driven by an autoimmune process: genes and environment are involved• Autoimmune diseases such as Celiac Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis (MS),

Rheumatoid arthritis (RA) etc have similar pathology and increase the size of the target market

• Improved understanding of the pathology of T1D enables earlier diagnosis, identification of at-risk scenarios and provides the potential for prevention and treatment to preserve, regenerate or replace beta-cells

• The importance of incentive models and data-driven approaches are showing promise in improving outcomes, and reimbursed, for both T1D and T2D

WHY WE FOCUS ON DIABETES – THE TIMING IS RIGHT

10

DIABETES – $60 BILLION+ MARKET FOR DRUGS & DEVICES

Source: http://www.strategyr.com/MarketResearch/Blood_Glucose_Blood_Sugar_Monitoring_Devices_Market_Trends.asp, https://globenewswire.com/news-release/2016/08/25/866781/0/en/Human-Insulin-Market-Poised-to-Surge-from-USD-27-0-Billion-in-2015-

to-USD-43-6-Billion-Globally-by-2021-ZionMarketResearch-Com.htm,l, http://seekingalpha.com/article/3971708-medtronics-insulin-pump-deal-shows-size-mattershttps://globenewswire.com/news-release/2015/09/24/770740/10150477/en/US-445-8-Million-Worth-

of-Continuous-Glucose-Monitoring-Systems-to-be-Sold-by-End-of-2015-Future-Market-Insights.htmlhttps://globenewswire.com/news-release/2016/07/05/853712/0/en/Antidiabetics-Market-size-worth-USD-116-Billion-by-2023-Global-Market-Insights-Inc.html

$10 billion

US glucose monitoring

market

$700 million

$30 billion

US insulin pump market

US insulin market

$450 million

US CGM market

$20 billion

US antidiabetesmarket

http://www.strategyr.com/MarketResearch/Blood_Glucose_Blood_Sugar_Monitoring_Devices_Market_Trends.asphttps://globenewswire.com/news-release/2016/08/25/866781/0/en/Human-Insulin-Market-Poised-to-Surge-from-USD-27-0-Billion-in-2015-to-USD-43-6-Billion-Globally-by-2021-ZionMarketResearch-Com.htm,lhttp://www.directory.ac/files/dumblists/logos/novartis.jpg

11DIABETES

LYFEBULB

• 5.7% of venture financings in diabetes between 2005-2014, while 24.2% in oncology

• 5.3% of IPO capital into diabetes companies, with 22.8% in oncology

• 3% of M&A and licensing deals were in diabetes drugs, diagnostics or devices, while 26% and 28% were in oncology and infectious disease respectively

• Perception of a lifestyle disease with untapped potential for smart investors

LESS CAPITAL TO THE DIABETES SECTOR AS COMPARED TO COMPARABLES

12DIABETES

LYFEBULB

2 Partnerships incl $5M

investments by Novo Nordisk

and Lilly toward an automated

insulin delivery system

2016 and 2017

Series A financing for its

automated insulin delivery

system; Collaboration with Abbott

$35.5M

2016. 2017

Acquisition of Animas by Johnson

& Johnson, for its consumer-

friendly insulin pump

$518M

2006

Series C financing for its

diabetes management system

$44.5M

2016

• Animas and Dexcom investors yielded high ROI through sale to JNJ and an IPO • Patients benefited from insulin pumps and continuous glucose monitoring systems, showing improved

glucose control and better outcomes • In recent years, investors have focused on fully automated systems, Bigfoot and BetaBionics, and overall

diabetes management tools, Livongo• Improves compliance and glucose control but do not CURE the patients

• Breakthrough technologies such as cell therapy and vaccines have even bigger potential

Initial Public Offering 2005

Current Stock px: $81

Market cap: $6.9B

EVIDENCE THAT PLACING THE RIGHT BETS YIELDS FINANCIAL AND PATIENT GAINS

THE TEAM

LYFEBULB

14THE TEAM

KARIN HEHENBERGER

MD, PhD

CEO and Founder, Lyfebulb

Fund Manager, Lyfebulb Ventures

LYFEBULB

STEPHEN SQUINTO,

PhD

Chairman, Lyfebulb

Director, Lyfebulb Ventures

Venture Partner, Orbimed

(Co-founder and former COO Alexion)

ANNA HEHENBERGER,

JD

General Counsel, Lyfebulb

Operations, Lyfebulb Ventures

ANTHONY SUN

MD

Investment Advisor,

Lyfebulb Ventures

CEO Zeno Pharmaceuticals, Inc.

Former Partner, Aisling capital

THE TEAM

15THE TEAM

MICHAEL BEALMEAR

Software Executive and

Entrepreneur

LYFEBULB

RICCARDO BRAGLIA

Co-founder Lyfebulb

CEO and Vice Chairman,

Helsinn Holdings

ALAN LEWIS, PhD

CEO, Diavacs

(Former CEO JDRF, Viacyte)

LISA RICCIARDI

Former SVP Pfizer, Medco,

Venture partner Essex

Woodlands

THE EXECUTIVE BOARD

16THE TEAM

Robert Langer, PhD, Chair

David H. Koch Institute Professor, Massachusetts Institute of Technology: Innovation, Biomedical engineering

1,380 articles, over 1,130 issued and pending patents worldwide, licensed or sublicensed to over 300 pharmaceutical, chemical,

biotechnology and medical device companies

Mark Atkinson, PhD

Professor, University of Florida, Gainesville, Immunology and Diabetes

More than 350 articles, recipient of numerous awards in the space of diabetes, second most cited investigator in diabetes

Richard Insel, MD

Former Chief Scientific Officer, JDRF

Oversaw JDRF’s scientific portfolio for over 10 years, 26 year tenure at Univ Rochester, Scool of Medicine, scientific co-founder

Praxis which developed a vaccine for childhood meningitis

Åke Lernmark, MD, PhD

Professor, Lund University, Immunology and Diabetes

More than 500 articles,, discoverer of GAD65 antibodies, genomics and pathogenesis of T1D

LYFEBULB

SCIENTIFIC ADVISORY BOARD

17THE TEAM

• Global approach, including North America, Europe, China, Australia, India and Israel• Representatives from clinical diabetes, deep science and digital health, chaired by Bob Langer, one of the most

successful scientists to date

Jianping Weng, MD, PhD

Professor, SunYat-sen University, China; Endocrinology and Diabetes

Chang Jiang Scholar, Ministry of Education, IDF Head China

Leonard Harrison, MD, PhD

Professor, Walter and Eliza Hall; Australia; Population health and Immunity

Yuval Dor, PhD

Professor, Hebrew University, Israel;

Head of developmental biology and cancer research

Brij Mohan Makkar, MD

Professor, Delhi Diabetes Center, India; Endocrinology and Diabetes

LYFEBULB

GLOBAL SCIENTIFIC ADVISORY TEAM

18THE TEAM

LYFEBULB

Anthony Sun, MD

CEO, Zeno, Former Partner, Aisling Capital

IPOs: Versartis (VSAR), Paratek (PRTK), Quintiles (Q), Vivus (VVUS), Trade sales: Cynapsus (Sold to Sunovion),

RetroSense (Sold to Allergan), MAP Pharma (MAP; Sold to Allergan)

Donald A. Lucas

Chairman, Lucas Venture Group

Led investments in: DexCom (NASDAQ: DXCM),), Avinger(NASDAQ:AVGR), Obalon (OBLN:Nasdaq). Coulter

Pharmaceutical (acquired by GlaxoSmithKline - GSK:NYSE). Early investor in: Intuitive Surgical

(ISRG:Nasdaq), Palantir, Oracle (ORCL: Nasdaq), Adobe/Macromedia(NASDAQ:ADBE) and Berkeley lights, Inc

INVESTMENT COMMITEE TRACK RECORD

LYFEBULB

VENTURES

20LYFEBULB VENTURES

• Driven by a strong scientific compass, while also placing importance on regulatory pathways, business plans and marketability of any approach

• Strong Team with extensive medical science, operational and investment experience

• Global network in the diabetes, life sciences and investment communities

• Unique Pipeline through our Team, network, and our Patient Entrepreneurs

• Leverage through the Lyfebulb Network and Market place to enhance visibility for Lyfebulb Ventures and its portfolio companies

DIFFERENTIATION

21LYFEBULB VENTURES

CURE

TREAT

PREVENT

REGENERATIVE MEDICINE

IMMUNOLOGY

BEHAVIOR MODIFICATION

Mobile Apps

Hepatic & Glucose-Sensitive Insulin

T2D

T1DVaccines

Microbiome

Cell Replacement

Cell Regeneration

Closed Loop

Incentive Models

GLUCOSE CONTROL

SCOPE: DIABETES AND AUTOIMMUNE DISEASE

22LYFEBULB VENTURES

• The time is right for new therapies and cures in diabetes:• Multiple blockbuster drugs have been launched in the past ten years for other

autoimmune diseases• Improving outcomes is being reimbursed, including adherence methods, incentive

models, opening up for platform technologies

• Focus on immunology, regenerative medicine, disruptive medical device and healthcare IT, areas where platform technologies could be expanded into other autoimmune and chronic diseases

• All-star scientific and investment teams• Global representatives from the diabetes research and technology space

• Multiple examples of higher than above ROI in the life sciences space (diabetes)• Novo Nordisk, Lilly, Minimed, Animas, Dexcom, Insulet, etc etc

OPPORTUNITY

23LYFEBULB VENTURES

• Preventing/arresting cell destruction:• Earlier diagnosis using autoantibody biomarkers• Immune modulation using targeted immune therapies, potentially used as combination therapies

• Regenerating existing beta-cells using drug therapy that stimulates growth and prevents destruction

• Replacing beta-cells using cell therapy, immunology and/or a protective device• Xeno, embryonic and adult stem cells• Transdifferentiation

• Disruptive devices including approaches to “close the loop”

• Leveraging big-data to understand patterns and modify behavior

• Out-of-the box solutions including glucose-sensitive insulin

TYPES OF INVESTMENTS

24LYFEBULB VENTURES

• COMPANY 1: Raising $300,000 toward completing animal studies for a nanotechnology device aimed to protect cells replacing the missing beta-cells in type 1 or late-stage type 2 diabetes

• COMPANY 2: Raising $250,000 toward completing clinical proof of concept for a peptide mix that intends to reduce hypoglycemia in pump-treated T1D (and T2D) patients

• COMPANY 3: Raising $500,000 toward IND in T1D for a novel nanotechnology that upregulates natural autoregulatory T cells in the pancreas – applications for other autoimmune disease

• COMPANY 4: Raising $12M as convertible debt or equity toward a technology modification in a pivotal trial for the first cell therapy company in T1D (T2D)

• COMPANY 5-10: leverage our global reach and finding young, upcoming scientists who can solve key questions!

LYFEBULB

EXAMPLES OF TYPES OF COMPANIES LYFEBULB VENTURES IS TARGETING

25LYFEBULB VENTURES

LYFEBULB

• The Fund: organized as a Delaware limited partnership, with Lyfebulb LLC as a member of the General Partner• Robust management and leading expert advisors • Size: $20 million anticipated

• Expected investments up to twenty companies, focused on autoimmune diabetes: preventing, halting the progression, curing the disease and improving outcomes and quality of life

• Each target receiving between $500K to $1M; allowing for follow-ons for a total of $1-3M each • Board seats will be important to each investment • Investment period 1-3 years, followed by a 1-2 year exit period

• Minimum investment $100,000; co-investments may be permitted on individual negotiated terms • Investment Committee seats accompany $5 million+ investments • Limited partners include existing Lyfebulb investors

• Fund fees: 2% management fee and 20% performance fee • Simple waterfall, no clawback

• Second Fund expected to be raised after 3 years

LYFEBULB VENTURES TERMS

26LYFEBULB VENTURES

LYFEBULB

• Innovative technology

• Addressing an unmet medical need

• Large potential market opportunity

• Established legal entity

• IP at least filed

• Strong team

• Solid business plan

INVESTMENT CRITERIA

27

CONCLUSIONS

28CONCLUSIONS

• Diabetes and autoimmune disease are global pandemics with severe medical and financial consequences – the unmet patient need remains large

• We are creating Lyfebulb Ventures, with the goals to deliver superior return on investment and to remove the burden of diabetes and autoimmune diseases

• The focus of the fund is in transformative therapies and cures of diabetes, including immunology, regenerative medicine, devices and big data – areas primed for success, because of their platform potential and recent scientific development in immunology and the improved understanding of diabetes pathology and disease progression

• Our strong team, global reach, tremendous network, operational experience, as well as Lyfebulb’s presence as a force in the diabetes community differentiate us from other entities

LYFEBULB

CONCLUSIONS